DOCSLIB.ORG

The Influence of Psychoactive Drugs on Brain Self-Stimulation Behaviour

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Influence of Psychoactive Drugs on Brain Self-Stimulation Behaviour PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/147779 Please be advised that this information was generated on 2021-10-04 and may be subject to change. The influence of psychoactive drugs on brain self-stimulation behaviour A. Wauquier The influence of psychoactive drugs on brain self-stimulation behaviour A. Wauquier D/1976/1060/65 Promotores: Prof. Dr. J.M.H. VOSSEN Prof. Dr. J.M. VAN ROSSUM The influence of psychoactive drugs on brain self-stimulation behaviour Proefschrift ter verkrijging van de graad van doctor in de Sociale Wetenschappen aan de Katholieke Universiteit te Nijmegen, op gezag van de Rector Magnificus prof. dr. A.J.H. Vendrik volgens besluit van het College van Decanen in het openbaar te verdedigen op vrijdag 8 oktober 1976 des namiddags te 4.00 uur door ALBERT WAUQUIER geboren te Menen Drukkerij Daneels, Beerse, Belgium 1976 3 Aan Annie 4 Acknowledgements The author would like to thank all those who have contributed to the realization of this study whether or not they are explicitly mentioned here. The assistance of Dr. P.A.J. Janssen in providing the opportunity to perform the experiments in optimal conditions in his laboratory is grate­ fully acknowledged. His interest and suggestions have stimulated much of the present work. Dr. C.J .E. Niemegeers's constructive criticism of many of the experiments has been much appreciated. It is to him that I owe my education in the field of pharmacology. Many thanks are due to my co-workers Messrs. J. Fransen, W. Melis and W. Van den Broeck, without whose excellent technical assistance these experiments could not have been carried out. Calculations and statistical evaluations were carried out in an expert fashion by Mr. G. Claessen and co-workers Miss M. Mertens, Mrs. M.J. Princen and Mr. R. Van Beek. I am also indebted to Mr. L Desmedí for his help with the more sophisticated statistical analysis. I would further like to acknowledge the valuable discussions with my colleague Mr. F.C. Colpaert and the suggestions by Prof. Dr. W. Soudijn and Dr. van Wijngaarden. The technical and electronic equipment was manufactured in the Janssen Scientific Instruments Division under the skillful guidance of Ing. H. Geivers, Ing. R. Nuyens and Mr. L. de Proost. I am very grateful to them and those who built the apparatus. Preparing the manuscript of this study also involved the assistance of many people. I would like to thank, firstly, Mrs. A. Nuyts who carried out the secreterial burden with friendly patience and Messrs. H. Vermeer and J. Van Mierlo for their skillful preparation of the graphs and figures. My sincere thanks are also due to Mrs. V. van Kesteren and Mr. H. Vanhove for their help in correcting the manuscript and Mr. A. Op de Beeck and his department, for their professional realization of the design and final printing. 5 Contents Chapter I: Introduction 10 Chapter II: Aims of the study 14 Chapter III: The influence of psychoactive drugs on brain self- stimulation: a literature survey 16 1. Material collection 1.1. Classification i.2. Key to the tables 1.3. Tables 2. Discussion 2.1. Methodology 2.2. Drug-analysis 2.3. Theoretical aspects Chapter IV: General methods 80 1. Subjects 2. Surgery 3. Materials 3.1. Cage 3.2. Electrode 3.2.1. Metal 3.2.2. Monopolar vs. bipolar stimulation 3.3. Stimulator and electrical parameters 3.3.1. Considerations on wave-form and current character­ istics 3.3.2. Stimulator and recording 4. Establishment of self-stimulation Chapter V: The influence of various stimulus parameter com­ binations 87 1. Excitability of neuronal tissue with respect to self-stimulation 2. Experimental study 2.1. Experimental procedures 2.2. Results 2.3. Discussion Chapter VI: The influence of various psychoactive drugs on brain self-stimulation behaviour: an experimental study 106 1. Test procedures 7 2. Control results: analysis of variance 2.1. Definition of variables 2.2. Design 2.3. Some remarks concerning the fundamental assumptions in the analysis of variance. 2.4. Results 2.5. Discussion 3. Drug effects 3.1. Introduction 3.2. CNS-stimulants 3.2.1. Cocaine 3.2.2. Amphetamine 3.2.3. Apomorphine 3.2.4. Conclusion 3.2.5. Discussion 3.3. Cholinergics and anticholinergics 3.3.1. Cholinergics 3.3.2. Anticholinergics 3.3.2.1. Dexetimide 3.3.2.2. Benztropine 3.3.2.3. Scopolamine 3.3.3. Conclusion 3.3.4. Discussion 3.4. Minor tranquillizers 3.4.1. Chlordiazepoxide 3.4.2. Diazepam 3.4.3. Nitrazepam 3.4.4. Conclusion 3.4.5. Discussion 3.5. Narcotic analgesics 3.5.1. Morphine 3.5.2. Fentanyl 3.5.3. Piritramide 3.5.4. Conclusion 3.5.5. Discussion 3.6. Antidepressants 3.6.1. Desipramine 3.6.2. Amitriptyline 3.6.3. Dexamisole 3.6.4. Conclusion 3.6.5. Discussion 3.7. Hypnosedatives 3.7.1. Etomidate 3.7.2. Methohexital 3.7.3. Pentobarbital 3.7.4. Conclusion 3.7.5. Discussion 3.8. General discussion 8 Chapter VII: Neuroleptics and brain self-stimulation 114 1. Introduction 2. The involvement of dopamine in brain self-stimulation. 3. The influence of neuroleptics on self-stimulation. 3.1. Methods 3.2. Results 3.2.1. General description 3.2.2. Dose-effect relationship 3.2.3. Potency 3.2.4. Control base-line 3.2.5. Discussion 4. Lick-experiment 4.1. Methods 4.2. Results 4.3. Discussion 5. Implantation site and species differences 5.1. Implantation site 5.2. Species 5.2.1. Introduction 5.2.2. Methods 5.2.3. Results 5.2.4. Conclusion 6. Self-stimulation and psychotropic assays. 6.1. Classification of neuroleptics 6.1.1. Classification based on potency ratios 6.1.2. Spectral map analysis 6.2. Positioning of psychotropic assays. 7. Studies on drug-interaction 7.1. Literature on neuroleptic-anticholinergic interaction 7.2. Reversal of the specific inhibition obtained with anticholin­ ergics. 7.2.1. Differentiation from narcotic analgesics 7.2.2. Dose-related antagonism 7.2.3. Antiparkinsonian drugs 7.3. Differential antagonisms 7.3.1. Differential antagonism between the neuroleptics 7.3.2. Specificity of the antagonists 7.4. General discussion 8. Conclusions 8.1. Impairment of self-stimulation 8.2. Clinical implications References 208 Summary 247 Samenvatting 250 Curriculum vitae 254 9 I. Introduction The present study deals with the influence of psychoactive drugs on self- stimulation behaviour in the rat. The term «self-stimulation» denotes the particular behaviour performed by the rat, in order to obtain electrical stimulation through chronically implanted electrodes in the brain. The discovery of self-stimulation by Olds and Milner (1954) occurred accidentally, but it was the start of numerous studies (see survey in: Brain stimulation reward; Wauquier and Rolls, 1976). In 1953, Jim Olds worked as a postdoctoral fellow together with the graduate student Peter Milner, who was experienced in surgical and electronic techniques, at McGill University in Canada. Olds was interested in the neurophysiology of learning. For this purpose, he used the rather new and still crude technique of chronically indwelling brain electrodes. These electrodes were aimed at the reticular formation, which was stimulated during learning at chosen points in a simple maze. During one of these experiments Olds observed that a rat did not run into an arm of the maze, but, rather, returned to the place where it had previously received brain stimulation. In the light of the experiments of Delgado et al. (1954), who showed the brain stimulation could elicit eversive reactions, it occurred to Olds that the rat apparently «liked» the stimulation. The behaviour could be evoked repeatedly and Olds together with Milner aimed to quantify this behaviour. For this purpose, the rat was placed into a Skinner box equipped with a lever, on which pressing evoked brain stimulation. To their surprise, the rat rapidly started to press the lever. Moreover, the rat continued for many hours and Olds, being afraid that this would not be repeatable, collected many meters of paper with cumulative recordings of the rat's activity. Although not certain, because histology could not been studied, it is likely that the electrode they had implanted went deeper than originally planned and arrived in the hypothalamic region. During subsequent weeks, many rats were implanted and it was confirmed that rats could be trained to press a lever for direct brain stimulation in septal and other regions. Olds and Milner reported their original findings in 1954, and papers attractively entitled «Pleasure centres in the brain?» reached the public press. The phenomenon self-stimulation (term introduced by Brady, 1955) gained a world-wide popularity. The experiments of Delgado et al. (1954) on the one hand, and Olds and Milner (1954) on the other hand, suggested that «hell and heaven» were detected in brain. During the years following the discovery, self-stimulation was shown in many species throughout the whole phylogenic scale, including Man. 10 Sem-Jacobsen and Torkildsen (1960) and Heath and Mickle (1960) (see survey by Sem-Jacobsen, 1976) demonstrated during stereotaxic surgery that electrical stimulation of particular brain areas in Man was experienced as pleasant. It is not without significance that a symposium dedicated to electrical brain-stimulation was entitled «The role of pleasure in behaviour» (Heath, 1964). This reflected the belief that pleasure could be caused directly in the brain by electrical current. Feibleman wrote: «The best interpretation seems to indicate that the stimulated animals are experiencing pleasure» (Feibleman, 1964).
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe Et Al
    US 2011 01 05536A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe et al. (43) Pub. Date: May 5, 2011 (54) DOSING REGIMENASSOCATED WITH Publication Classification LONG-ACTING INUECTABLE PALIPERDONE ESTERS (51) Int. Cl. A 6LX 3/59 (2006.01) (76) Inventors: Peter H. Lewyn-Briscoe, A6IP 25/18 (2006.01) Newtown, PA (US); Cristiana Gassmann-Mayer, Pennington, NJ (US); Srihari Gopal, Belle Meade, (52) U.S. Cl. ................................................... S14/259.41 NJ (US); David W. Hough, Wallingford, PA (US); Bart M.M. Remmerie, Gent (BE); Mahesh N. (57) ABSTRACT Samtani, Flemington, NJ (US) The present application provides a method for treating (21) Appl. No.: 12/916,910 patients in need of psychiatric treatment, wherein said patient (22) Filed: Nov. 1, 2010 misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides Related U.S. Application Data a method for treating psychiatric patients in need of a Switch (60) Provisional application No. 61/256,696, filed on Oct. ing treatment to paliperidone palmitate in a Sustained release 30, 2009. formulation. Patent Application Publication May 5, 2011 Sheet 1 of 6 US 2011/O105536 A1 FIG. 1 First-Order PrOCeSS Cp V CL Central (2) Zero-Order PrOCeSS Patent Application Publication May 5, 2011 Sheet 2 of 6 US 2011/O105536 A1 FIG. 2 25mgeq 50mgeq m-100mde::::: Missed doSe On WK 4. Patient returns On WK5 Missed doSe On WK 4. Patient returns On WK 6 -8-4 O 4 8 12 16 2024 -8-4 O 4 8 12 1620 24 Missed doSe On WK 4.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley Et Al
    USOO6197764B1 (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley et al. (45) Date of Patent: *Mar. 6, 2001 (54) CLOZAPINE COMPOSITIONS AND USES FOREIGN PATENT DOCUMENTS THEREOF 0599 576A1 1/1994 (EP). (75) Inventors: Matthews O. Bradley, Laytonsville, 693498 1/1996 (EP). MD (US); Victor E. Shashoua, 61204136 11/1984 (JP). Belmont, MA (US); Charles S. 06-072868 3/1994 (JP). Swindell, Merion; Nigel L. Webb, 6072868 3/1994 (JP). Bryn Mawr, both of PA (US) 7082146 3/1996 (JP). 8151334 6/1996 (JP). (73) Assignee: Protarga, Inc., Conshohocken, PA (US) 9030963 2/1997 (JP). (*) Notice: Subject to any disclaimer, the term of this WO 89/07938 9/1989 (WO). patent is extended or adjusted under 35 WO 96/04001 2/1996 (WO). U.S.C. 154(b) by 0 days. WO 96/22303 7/1996 (WO). WO 96/27380 9/1996 (WO). This patent is Subject to a terminal dis WO98/17325 4/1998 (WO). claimer. OTHER PUBLICATIONS (21) Appl. No.: 08/978,541 (22) Filed: Nov. 26, 1997 Bourat, et al., "Long Chain Esters of Pipotiazine as Lon g-Acting Psychotropic Pro-Drug, Med. Chem. Proc. Int. (51) Int. Cl. .............................................. A61K 31/00 Symp. 5th (1976) pp. 105-114. (52) U.S. Cl. ........................... 514/218; 514/219; 514/220 Lohr, et al., “Neuroleptic-Induced Movement Disorders . (58) Field of Search ..................................... 514/218, 219, ..", Psychiatry, vol. 3, (1989). 514/220 Makino, et al., Chemical Abstracts, vol. 106, No. 12, (56) References Cited (90.177x) issued Mar. 23, 1987, “Pharmaceuticals Permeable to Blood-Brain Barrier'.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Targeting the Cellular Schizophrenia. Likely Employment of the Antipsychotic Agent Pimozide in Treatment of Refractory Cancers A
    Critical Reviews in Oncology / Hematology 128 (2018) 96–109 Contents lists available at ScienceDirect Critical Reviews in Oncology / Hematology journal homepage: www.elsevier.com/locate/critrevonc Targeting the cellular schizophrenia. Likely employment of the T antipsychotic agent pimozide in treatment of refractory cancers and glioblastoma ⁎ Ilhan Elmacia, Meric A. Altinozb,c, a Memorial University, Neuroacademy Group, Istanbul, Turkey b Neurooncology Branch, Neuroacademy Group, Istanbul, Turkey c Department of Psychiatry, Maastricht University, Holland, Turkey ARTICLE INFO ABSTRACT Keywords: Pimozide is currently being used in clinic as a neuroleptic and exerts versatile biological actions. Pimozide is a Pimozide cationic amphiphilic drug (CAD); CADs block the synthesis of neutral lipids, impair cholesterol homeostasis of Refractory cancers cancer cells and increase accumulation of diacylglycerol-3-phosphate. Pimozide exerts tumoricidal activity Glioblastoma which was first shown for melanoma and neuroblastoma via proposed anti- dopaminergic effects. Recently, pancreas cancers are shown to elevate dopamine receptor-2 synthesis, which is blocked by pimozide leading growth inhibition. Besides binding to inner mitochondrial membrane and reducing cellular respiration, pimozide also inhibits calmodulin, T-type calcium channels and σ-receptors which all correlate with tumor-inhibitory functions. Pimozide also exerts chemotherapy and radiotherapy-sensitizing effects in cancer cells and acts as an inhibitor of STAT-3 and STAT-5 signaling proteins with potential activity in leukemia, liver and prostate cancer. Pimozide also blocks stem cell features and Wnt-β/catenin signaling in liver cancer. Pimozide interferes with Fatty Acid Protein Binding-4 and activates PPAR-γ and it was proposed to alleviate cancer cachexia. Besides mechanisms of calmodulin and σ-receptor associated pathways, pimozide was proposed to inhibit glioblastoma via serotonin receptor 5-HT7.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen Et Al
    US 2008O161324A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen et al. (43) Pub. Date: Jul. 3, 2008 (54) COMPOSITIONS AND METHODS FOR Publication Classification TREATMENT OF VRAL DISEASES (51) Int. Cl. (76) Inventors: Lisa M. Johansen, Belmont, MA A63/495 (2006.01) (US); Christopher M. Owens, A63L/35 (2006.01) Cambridge, MA (US); Christina CI2O I/68 (2006.01) Mawhinney, Jamaica Plain, MA A63L/404 (2006.01) (US); Todd W. Chappell, Boston, A63L/35 (2006.01) MA (US); Alexander T. Brown, A63/4965 (2006.01) Watertown, MA (US); Michael G. A6II 3L/21 (2006.01) Frank, Boston, MA (US); Ralf A6IP3L/20 (2006.01) Altmeyer, Singapore (SG) (52) U.S. Cl. ........ 514/255.03: 514/647; 435/6: 514/415; Correspondence Address: 514/460, 514/275: 514/529 CLARK & ELBNG LLP 101 FEDERAL STREET BOSTON, MA 02110 (57) ABSTRACT (21) Appl. No.: 11/900,893 The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain (22) Filed: Sep. 13, 2007 embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particu Related U.S. Application Data lar embodiments, the viral disease is viral hepatitis (e.g., (60) Provisional application No. 60/844,463, filed on Sep. hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). 14, 2006, provisional application No. 60/874.061, Also featured are screening methods for identification of filed on Dec. 11, 2006. novel compounds that may be used to treat a viral disease.
    [Show full text]
  • Antipsychotics for Treatment of Delirium in Hospitalised Non-ICU Patients
    This is a repository copy of Antipsychotics for treatment of delirium in hospitalised non-ICU patients. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/132847/ Version: Published Version Article: Burry, Lisa, Mehta, S.R., Perreault, M.M et al. (6 more authors) (2018) Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews. CD005594. ISSN 1469-493X https://doi.org/10.1002/14651858.CD005594.pub3 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Database of Systematic Reviews Antipsychotics for treatment of delirium in hospitalised non- ICU patients (Review) Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews 2018, Issue 6.
    [Show full text]
  • Zebrafish Behavioral Profiling Identifies Multi-Target Antipsychotic-Like Compounds
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE HHS Public Access provided by Carolina Digital Repository Author manuscript Author ManuscriptAuthor Manuscript Author Nat Chem Manuscript Author Biol. Author Manuscript Author manuscript; available in PMC 2016 November 30. Published in final edited form as: Nat Chem Biol. 2016 July ; 12(7): 559–566. doi:10.1038/nchembio.2097. Zebrafish behavioral profiling identifies multi-target antipsychotic-like compounds Giancarlo Bruni1,†, Andrew J. Rennekamp1,2,†, Andrea Velenich3,†, Matthew McCarroll4,5, Leo Gendelev5,9, Ethan Fertsch4,5, Jack Taylor4,5, Parth Lakhani4,5, Dennis Lensen3, Tama Evron3, Paul J. Lorello6, Xi-Ping Huang7, Sabine Kolczewski8, Galen Carey3, Barbara J. Caldarone6, Eric Prinssen8, Bryan L. Roth7, Michael J. Keiser5,9, Randall T. Peterson1,2, and David Kokel4,5 1Cardiovascular Research Center and Division of Cardiology, Department of Medicine, Massachusetts General Hospital and Department of Systems Biology, Harvard Medical School, 149 13th Street, Charlestown, Massachusetts, 02129, USA 2Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA 3Teleos Therapeutics, 196 Boston Avenue, Suite 2400, Medford, MA 02155, USA 4Department of Physiology, University of California, San Francisco, California 94158, USA 5Institute for Neurodegenerative Disease, University of California, San Francisco, California 94143, USA 6NeuroBehavior Laboratory, Harvard NeuroDiscovery Center and Department of Neurology, Brigham and Women’s Hospital, 77 Avenue
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Developing a Neuronal Model for the Pathophysiology of Schizophrenia Based on the Nature of Electrophysiological Actions of Dopa
    REVIEW Developing a Neuronal Model for the Pathophysiology of Schizophrenia Based on the Nature of Electrophysiological Actions of Dopamine in the Prefrontal Cortex Charles R. Yang, Ph.D., Jeremy K. Seamans, Ph.D., and Natalia Gorelova, Ph.D. This review covers some recent findings of the same schizophrenic patient in the course of the illness. We electrophysiological mechanisms through which hypothesize that the dysfunctional mesocortical dopamine mesocortical dopamine modulates prefrontal cortical input to the PFC may lead to abnormal modulation of neurons. Dopamine has been shown to modulate several ionic channels distributed in the dendritic–somatic ionic conductances located along the soma-dendritic axis of compartments of PFC pyramidal neurons that project to the prefrontal cortical pyramidal neurons. These ionic currents ventral tegmental area and/or nucleus accumbens. In some include high-voltage-activated calcium currents and slowly schizophrenics, a reduction of mesocortical dopamine to inactivating Na1 and K1 currents. They contribute actively below optimal levels and/or a loss of local GABAergic in processing functionally segregated inputs during inputs may result in a dysfunctional integration of extrinsic synaptic integration. In addition, dopamine mainly associative inputs by Ca21 channel activity in the distal depolarizes the fast-spiking subtype of local GABAergic dendrites of PFC pyramidal neurons. This may account for interneurons that connect the pyramidal neurons. This the patients’ distractibility caused by their inability to focus latter action can indirectly control pyramidal cell only on relevant external inputs. In contrast, in acute stress excitability. These electrophysiological data indicate that the or psychotic episodes, an associated abnormal elevation of actions of dopamine are neither “excitatory” nor mesocortical dopamine transmission may greatly influence “inhibitory” in pyramidal prefrontal cortex neurons.
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]